OSE Immunotherapeutics announced that the Company is committed to the fight against COVID-19. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
• Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a T lymphocyte immune response for COVID-19
• Uses artificial intelligence algorithm from MAbSilico to accelerate optimization of epitopes able to induce a robust cell memory immunity
• First preclinical results expected start of H2 2020, possible clinical trial by year end